Patients older than 75 years who undergo cataract surgery report more frequent failure of the ocular surface after the procedure than those younger than 65 years; however, the prophylactic ...

Michelle Hessen, OD, spoke about the results of a new study evaluating the efficacy of cyclosporine ophthalmic solution 0.09% in patients with dry eye. This was a phase 4, single-arm, multicenter ...

Please provide your email address to receive an email when new articles are posted on . Cold instillation was associated with significantly lower discomfort compared with warm instillation. The relief ...

NASHVILLE, Tenn.--(BUSINESS WIRE)--Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced that VEVYE® (cyclosporine ophthalmic solution) 0.1%, a patented, non‑preserved, ...

VEVYE® is the First and Only Cyclosporine-Based Product Indicated for the Treatment of Both Signs and Symptoms of Dry Eye Disease with Efficacy Demonstrated After Four Weeks VEVYE® is the Only ...

This clinical brief provides a background on DED and reviews DED treatment and challenges associated with prescription eye drops. Stay ahead of policy, cost, and value—subscribe to AJMC for expert ...

BRIDGEWATER, N.J., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) (NASDAQ: AMRX) today announced the U.S. Food and Drug Administration (FDA) has approved ...

VEVYE® is the First and Only Cyclosporine-Based Product Indicated for the Treatment of Both Signs and Symptoms of Dry Eye Disease with Efficacy Demonstrated After Four Weeks NASHVILLE, Tenn. & ...

Amneal Pharmaceuticals (AMRX) announced the FDA has approved the company’s cyclosporine ophthalmic emulsion 0.05%, a sterile, preservative-free formulation supplied in single-use vials. The product is ...